Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02152254
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
- NCT02152254 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on NCT02152254 (targeted therapy based on molecular profiling and Standard-of-Care therapy in Metastatic Malignant Neoplasm) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02152254 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm
- Interventions
- Targeted Therapy Based on Molecular Profiling; Standard-of-Care Therapy
- Arms
- Arm A: Targeted Therapy · Active comparator
- Arm B: Standard-of-Care Therapy · Experimental
- Enrollment
- 1,362 (estimated)
- Primary outcomes
- Comparison of Progression-Free Survival (PFS) Between the Two Randomized Arms
- Sponsor
- M.D. Anderson Cancer Center with Tempus AI
- Start
- May 13, 2014
- Primary completion
- Dec 31, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT02152254 · updated Aug 10, 2026
Publications
linked from the registry- Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27;6(1):78. doi: 10.1038/s41698-022-00317-0. PubMed 36302890
- Naqvi MF, Vo HH, Vining D, Tsimberidou AM. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538. eCollection 2021. PubMed 33995588
- Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis. 2017 Feb;76(2):418-421. doi: 10.1136/annrheumdis-2016-209511. Epub 2016 Jul 25. PubMed 27457512